Adam is the COO and a board director for Oxford University Innovation Ltd (OUI), leading teams responsible for translating the University’s expertise, ideas and IP into societal benefits in the form of new products, services and companies. He has worked for more than 15 years in commercial roles encompassing general management, business development and licensing, new venture formation, product development and lobbying/advocacy. Prior to his current role Adam led the Life Sciences Licensing & Ventures Group at OUI, where he oversaw the formation of more than 20 new spin out companies and led the creation of LAB282, a £13M partnership with Oxford Sciences Innovation plc and Evotec AG to accelerate Oxford drug discovery activities. Between 2010 and 2013 Adam worked as Deputy General Manager for the Oxford-Emergent Tuberculosis Consortium Ltd, a joint venture between the University of Oxford and Emergent BioSolutions Inc, which raised more than $30M to conduct the first ever efficacy study of a next generation TB vaccine in infants. Prior to this Adam worked in healthcare consulting and then in increasingly senior commercialisation roles at OUI.